GC
ANIK icon

Guggenheim Capital’s Anika Therapeutics ANIK Stock Holding History

Guggenheim Capital’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,779
Closed -$234K – 2839
2016
Q4 		$234K Sell
4,779
-465
-9% -$21.5K ﹤0.01% 2660
2016
Q3 		$251K Sell
5,244
-186
-3% -$9.19K ﹤0.01% 2603
2016
Q2 		$291K Buy
5,430
+141
+3% +$6.64K ﹤0.01% 2552
2016
Q1 		$237K Buy
+5,289
New +$215K ﹤0.01% 2635
2015
Q4 		– Sell
-53,201
Closed -$1.69M – 2987
2015
Q3 		$1.69M Buy
53,201
+539
+1% +$18.8K 0.01% 1722
2015
Q2 		$1.74M Buy
52,662
+13,411
+34% +$478K ﹤0.01% 1873
2015
Q1 		$1.61M Buy
39,251
+8,069
+26% +$326K ﹤0.01% 1953
2014
Q4 		$1.27M Sell
31,182
-2,057
-6% -$80.4K ﹤0.01% 2069
2014
Q3 		$1.22M Sell
33,239
-7,223
-18% -$312K ﹤0.01% 2109
2014
Q2 		$1.87M Sell
40,462
-5,083
-11% -$226K ﹤0.01% 1878
2014
Q1 		$1.87M Sell
45,545
-14,990
-25% -$557K 0.01% 1841
2013
Q4 		$2.31M Buy
+60,535
New +$1.87M 0.01% 1650

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Guggenheim Capital's ANIK Position: Q1 2017 in Review

Guggenheim Capital sold out of Anika Therapeutics (ANIK) in Q1 2017, closing a stake of 4,779 shares — an estimated $234K sold.

Guggenheim Capital first reported a position in ANIK in Q4 2013 and held it in 12 quarters. The position peaked at $2.31M in Q4 2013. 156 funds tracked by Wall St. Rank hold ANIK as of Q1 2017.

  • Guggenheim Capital reported no remaining Anika Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Guggenheim Capital sold 4,779 Anika Therapeutics shares in Q1 2017, an estimated $234K.
  • Guggenheim Capital first reported a position in Anika Therapeutics in Q4 2013 and held it in 12 quarters.
  • Guggenheim Capital's Anika Therapeutics position peaked at $2.31M in Q4 2013.
  • 156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2017.

Based on Guggenheim Capital's 13F filing for Q1 2017, filed 15 May 2017.